Valuation: Exelixis, Inc.

Market Cap 13.4B 11.59B 10.82B 9.93B 18.67B 1,275B 18.96B 127B 49.76B 639B 50.3B 49.21B 2,113B P/E 2026 *
17.2x
P/E 2027 * 15.1x
Enterprise Value 12.65B 10.95B 10.22B 9.38B 17.63B 1,205B 17.9B 120B 47B 603B 47.51B 46.47B 1,996B EV / Sales 2026 *
4.94x
EV / Sales 2027 * 4.07x
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day+3.58%
1 week-3.39%
Current month+1.96%
1 month-2.63%
3 months+11.03%
6 months+23.17%
Current year+23.36%
1 week 51.76
Extreme 51.76
56.95
1 month 51.76
Extreme 51.76
57.42
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Free

Director

8,367 0.0033%
2/26/26 Free

General Counsel

23,119 0.0086%
2/26/26 Free

Executive/Senior Manager

40,459 0.0151%
Change 5-day change 1-year change 3-year change Capi.($)
+3.58%-3.39%+43.38%+166.75% 13.12B
+8.49%+23.38%+65.44%+104.90% 62.92B
+1.25%+2.22%+31.00%+70.51% 54.32B
+2.72%+0.88%-15.84%-12.03% 22.91B
-1.09%+29.18%+17.83%+496.18% 28.73B
+10.83%+21.32%+45.03%+2.02% 21.65B
+6.50%+8.41%+45.17%-21.02% 17.76B
-3.88%+20.98%+201.07%+350.94% 16.47B
+6.20%+12.16%+28.51%+629.05% 15.48B
+2.12%+0.38%+437.40%+176.94% 12.12B
Average +3.67%+6.51%+89.90%+196.42% 26.55B
Weighted average by Cap. +4.10%+9.41%+65.37%+165.48%

Financials

2026 *2027 *
Net sales 2.56B 2.22B 2.07B 1.9B 3.57B 244B 3.62B 24.27B 9.51B 122B 9.62B 9.41B 404B 2.89B 2.5B 2.33B 2.14B 4.03B 275B 4.09B 27.39B 10.74B 138B 10.85B 10.62B 456B
Net income 810M 701M 655M 601M 1.13B 77.16B 1.15B 7.68B 3.01B 38.66B 3.04B 2.98B 128B 941M 814M 760M 698M 1.31B 89.57B 1.33B 8.92B 3.49B 44.88B 3.53B 3.46B 148B
Net Debt -744M -644M -601M -552M -1.04B -70.87B -1.05B -7.05B -2.77B -35.51B -2.8B -2.73B -117B -1.62B -1.4B -1.31B -1.2B -2.26B -154B -2.3B -15.38B -6.03B -77.39B -6.09B -5.96B -256B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-08-07 $54.07 +3.58% 3,440,082
26-08-06 $52.20 -7.94% 5,410,948
26-08-05 $56.70 +1.25% 4,202,047
26-08-04 $56.00 +1.71% 2,729,948
26-08-03 $55.06 +3.83% 4,301,629
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
52.20USD
Average target price
52.00USD
Spread / Average Target
-0.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock